Basel. 13–14 October.

Twenty-One Years On. The Same Room. A Different Conversation.

Now in its 21st year, Biomarkers, CDx & Precision Medicine Europe is the flagship European event for biomarker validation, companion diagnostics and AI-driven precision medicine.

In 2026 it co-locates with NextGen Omics, Tech & Data at Congress Centre Basel. 
The IVDR-shaped regulatory landscape, the AI-driven diagnostic technologies, and the senior pharma, regulatory, academic and healthcare audiences reshaping European clinical practice are all in one place for two days.

The Formats

Pre-arranged One-to-one Meetings

At Biomarkers, CDx & Precision Medicine Europe, pre-arranged meetings with solution and technology providers are a structured part of the event.

The value sits in the matches that are not obvious. A biomarker validation team meeting a computational pathology platform they were not aware of. A CDx programme meeting a regulatory consultancy that has walked the IVDR pathway. The kind of conversation that is hard to engineer any other way.

In a field moving as fast as precision medicine, that matters more than it used to.

Collaboration Hubs

Four registration-required Collaboration Hubs run alongside the conference.

The Day 1 Hubs cover AI in precision medicine, moderated by Günter Schmidt (VP Image Data Sciences, Computational Pathology, AI for Science Innovation, AstraZeneca); and pharma, start-up and academia partnering in omics and precision medicines, moderated by Raif Yuecel of the University of Exeter.

The Day 2 Hubs cover research-to-clinic translation, moderated by Richard Barker (Co-Founder & CEO, New Medicine Partners); and multi-centre networks and consortia for genomic medicine.

Capped attendance. Invited specialists. Fifty minutes behind closed doors. The format that produces the most direct exchange of the two days.

Closed-Door Panels

Two invite-only closed-door panels run on the Day 1 lunchtime, outside the main programme.

One on the Multi-Omics Investment Landscape, where VCs, founders and senior pharma BD voices discuss the recent shift in funding outlook, how breakthrough science becomes investible, and how the regulation and reimbursement landscape is reshaping early-stage diagnostics.

One on Unlocking Population Genomics with Large Scale Cohort Studies, with Aarno Palotie of FIMM carrying the FinnGen thread directly from his Day 1 plenary into the closed-door room.

These are not panels designed for an audience. They are structured conversations for the people in the room.

Day 2 Roundtable Sessions

Day 2 opens with eight parallel roundtable sessions across four conference rooms. Each table seats senior peers around one specific challenge from the wider programme — biomarker, CDx, multi-omics, spatial biology or computational pathology — for a focused conversation in a small group setting.

The roundtables are designed to surface the questions that don't make it onto a main-stage panel. The format pulls VP and Director level delegates into the room before the day formally begins.

The Investing in Precision Medicine Breakfast

Day 2 also opens with a separate breakfast session, this one bringing senior pharma R&D leaders, biotech founders, BD heads and the investor community into one room. The conversation runs on what investors are funding in precision medicine right now, what founders need to bring to a fundraise in 2026, and what role investors play beyond writing the cheque.

It pairs with the Day 1 Multi-Omics Investment Landscape panel for delegates tracking the funding side of the field.

The Start-Up Zone

Building an omics, biomarker, AI pathology or precision diagnostics company? The Start-Up Zone gives early-stage teams a stage in front of the same 1,000+ senior pharma, biotech, academic and healthcare audiences.

The Event in Numbers

1000

senior pharma, biotech, regulatory and academic delegates across both co-located events

90
partners exhibiting across the two days
17

content tracks across four programmes

10
of pre-arranged 1:1 meetings

Key Event Highlights

An unmissable journey awaits you: from a high-energy AI & Data Zone to celebrated keynote speakers. Discover the moments that will transform your Biomarkers, CDx & Precision Medicine experience.

Who Will Be in the Room?

Over 1,000 senior attendees across the two co-located events. The audience split is 65% pharma and biotech, 20% healthcare, and 15% academic. Most delegates work directly in biomarker validation, CDx development, regulatory affairs, computational pathology, AI in diagnostics, multi-omics and clinical translation.

Over 110 confirmed speakers in total across the two days, drawn from the senior pharma R&D, regulatory, computational pathology, and academic communities defining the field in Europe.

Confirmed Highlighted Speakers include Johan Luthman (EVP and Head of R&D, Lundbeck), Günter Schmidt (VP Image Data Sciences, Computational Pathology, AI for Science Innovation, AstraZeneca), Rene Kubiak (Global Head of Translational Medicine and Research Statistics, Sanofi), Marta Milo (Director of Computational Oncology, Oncology Data Science & AI, AstraZeneca), Arianna Sabò (Head of Research and Discovery, Quantro Therapeutics), Emma Huang (VP and Head of Experimental Medicine, Engitix Therapeutics) and Liliana Greger (Senior Director of Bioinformatics, Amphista Therapeutics).

BIOMEU Who will be in the room 1
BIOMEU Who will be in the room 2
BIOMEU Who will be in the room 3

2025 Programme Highlights

Explore dynamic panels, engaging roundtables, and hands-on workshops designed to drive innovation and foster collaboration, including:

NGS, CLINICAL OMICS & DIAGNOSTICS 
Panel Discussion: Overcoming Multi-Omics Data Harmonisation & Analysis Challenges 

Moderator: RUSLAN SADREYEV, Director of Bioinformatics & Assistant Professor, Massachusetts General Hospital
Panellists: 
ARIDAMAN PANDIT, Senior Principal Research Scientist, AbbVie 
FELIX FRANCIS, Sr. Manager, Data Management and Analytics Technology Lead, Takeda 
LUCA PINELLO, Associate Professor of Pathology, Harvard Medical School 
MEDHI DAMAGHI, Assistant Professor & Group Leader, Stony Brook University 
SIMONA CRISTEA, Head of Genomics Data Science & AI, Dana-Farber Cancer Institute 
LUCAS SCHÜTZ, Chief Operational Officer, AriadneAI 

SINGLE CELL 
Presentation: Comparative Insights In Single Cell RNA-seq & Advances In Large-Scale Multimodal Profiling

ZORA MODRUSAN, Senior Director of NGS, Genentech

SPATIAL MULTI-OMICS
Panel Discussion: Guiding Immuno-Oncology Breakthroughs With Spatial Biology

Moderator: ALINA AINBINDER, Scientific Associate Director, Oncology, Takeda
Panellists:
JASMINE PLUMMER, Director, St. Jude Children’s Research Hospital
JIA-REN LIN, Technical Director of Tissue Imaging Platform, Harvard Medical School
NIR BEN CHETRIT, Assistant Professor, Weill Cornell Medicine
COLLES PRICE, Scientific Associate Director, Takeda
YASSER RIAZALHOSSEINI, Associate Professor & Head of Cancer Genomics, McGill University

CROSS PROGRAMME  
Breakfast Roundtables - with topics including 

•   The Potential Of Multi-Omics In Cell & Gene Therapies
•    New Frontiers In Liquid Biopsies
•    Integrating Single Cell Data Across Samples
•    Overcoming Cell Segmentation Challenges In Multiplex Immunofluorescence Biomarker Imaging
•    Single Cell Multi- Omics Integration– From The Pharma Perspective
•    Safety Biomarkers In The Age Of Spatial Biology
•    Harnessing Spatial Transcriptomics In Immunoscience
•    Spatial Analysis Of Cancer Data
•    Advancing Spatial Biology Using The Complexities Of Immune Cell Interactions In

Computational Pathology Hackathon

The Computational Pathology Diagnostic Solution Hackathon will bring together clinicians, pathologists, AI experts, pharma biomarker teams, diagnostics partners, and regulatory stakeholders to develop practical computational pathology diagnostic solutions for real-world biomarker and clinical decision-making challenges. Focusing on 5 key questions, teams will have the chance to collaborate and discuss these challenges before providing a 10 minute presentation, with winners announced by our judges on the day.

Hackathon

Featured Speakers for Biomarkers, CDx & Precision Medicine 2026

Enchi Liu
Vice President & Head Experimental Medicine,
Lundbeck
Guillaume Cettou
Executive Director Diagnostics,
GSK
Isabella Gashaw
Head of Experimental Sciences CRM,
Boehringer Ingelheim
Jennifer Tucker
Global Head of Regulatory Affairs, Pathology Lab,
Roche Tissue Diagnostics
Maciej Cabanski
Vice President Biomarkers and CDx,
Monte Rosa Therapeutics
Omar El Nahhas
Chief Executive Officer & Co-Founder,
StratifAI GmbH
Özlem Akilli
Director Department of Spatial Biology and Cellular Dynamics,
TRON Translational Oncology Mainz
Rene Kubiak
Global Head Early Development & Non-Clinical Biostatistics,
Sanofi
Svetlana Mukhina
Director Global Regulatory Affairs, CDx,
Merck Healthcare KGaA
Adisa Trnjanin
Co-Founder & Co-Head,
ZHAW Life Sciences
Aditi Deshpande
Director, Biology,
Bioage labs
Alberto Valdeolivas Urbelz
Principal Scientist,
Roche
Andreia Soares
Scientific Director,
Synexa Life Sciences
Andrew Nelson
Senior Director,
Real Chemistry, Integrated Intelligence
Anissa Fries
Lead Scientist, Flow Cytometry,
Labcorp
Antonino Carbone
Chairman of the Department of Pathology,
Centro di Riferimento Oncologico di Aviano
Arijit Patra
Senior Principal Scientist,
Ucb
Bernhard Polzer
Head of Cellular and Molecular Diagnostics,
Fraunhofer Institute
Bogdan Munteanu
Lab Head Global Imaging Mass Spectrometry Biomarker Discovery Platform (DMPK),
Sanofi
Carsten Krantz
Associate Director,
Novartis
Catherine Gilbert
Field Application Scientist,
Seer
Céline Pallaud
Precision Medicine Strategy Head,
Novartis
Celine Vandamme
Director, Scientific Business Development,
CellCarta
Christoph Rohde
Head of Laboratory, Clinical Biomarkers and Technologies,
Merck Healthcare
Daniel Truhn
Professor of AI in Medicine,
RWTH Aachen University
David Fabrizio
VP, Commercial Strategy and Medical Innovation,
Foundation Medicine
David Klug
Professor of Chemical Biophysics, Department of Chemistry,
Imperial College London
David Latto
Associate Product Specialist Director ,
IQVIA Laboratories
Diego Saldana Miranda
Associate Director and Senior Data Scientist,
Novartis
Emmanouil Karteris
Professor in Biomedical Sciences,
Brunel University of London
Eric Letouzé
Head of Single Cell,
One Biosciences
Eshita Mutt
Senior Bioinformatics Support Scientist Proteomics Regional S&S,
Illumina
Espen Walker
Head of Global Medical Diagnostics,
AstraZeneca
Federico Pratesi
Senior Multiomics Sales Specialist,
Illumina
Florian Langer
Sales & Applications Manager,
Histomography GmbH
Georgia Cresswell
Research Services Business Development Manager,
Patholytix
Heleen Verlinden
Senior Director Alliance Management,
Muna Therapeutics
Helene Fachim
Clinical Research Manager,
Cure Parkinson's
Inês Santarino
Business Development Manager,
Cyentia Biosource
Jacek Lukawy
Innovation Program Director, Translational Medicine Clinical Sciences and Innovation/NIBR,
Novartis
Jan Lukas Robertus
Honorary Associate Professor, Imperial College London and Head of Pathology Department,
Royal Brompton & Harefield NHS Foundation Trust
Janne Martikainen
Professor, School of Pharmacy,
University of Eastern Finland
Jessica Apulei
Scientific Liaison Manager - EMEA,
Hologic Diagenode
Johan Lundin
Research Director,
Institute for Molecular Medicine Finland (FIMM), University of Helsinki
Johan Luthman
Executive Vice President & Head R&D ,
Lundbeck
John-Melle Bokhorst
Director of AI Research,
Indica Labs
Julia Jabs
Head of Biomarker Lab Histology,
Merck Healthcare KGaA
Junmei Cairns
Associate Director,
AstraZeneca
Karthikeyan Devaraju
Senior Scientist,
Cerba Research
Kathrin Heinzmann
Senior Biomarker Scientist,
Cancer Research UK
Kathrin Schlueter
Medical Affairs Manager,
BD
Katrien Grünberg
Professor of Pathology and Head of Pathology Department,
Radboud UMC
Kedar Natarajan
Professor,
Ashoka University
Konstantinos Venetis
Head of the R&D Team,
IEO Istituto Europeo di Oncologia
Konstanty Korski
Senior MD Pathologist,
Roche
Kristin Hellman
Global Product Manager,
Olink, part of Thermo Fisher Scientific
Krzysztof Kolmus
Principal Scientist,
Ingenix
Lorcan Sherry
Chief Scientific Officer,
OracleBio
Lucas Rifkin
Executive Medical Director, Global Head of Medical & Scientific Affairs,
Labcorp
Magda Meissner
Clinical Liquid Biopsy Lead,
Velindre University NHS Trust
Maham Ansari
Senior Director, IVD Regulatory,
Precision for Medicine
Marco Tecilla
Scientific Area Lead Digital Pathology,
Roche
Marie-Christine Bakker
MD-researcher in Medical Oncology,
UMC Utrecht
Mario Kreutzfeldt
Deputy Lab Manager,  Computational Pathology and Clinical Bioinformatics Laboratory,
Geneva University Hospitals (HUG)
Martí Jimenez Mausbach
Associate Scientific Director,
Novo Nordisk
Megan O’Shaughnessy
Scientific Affairs Specialist,
ICON
Michael Rebhan
Associate Director,
Novartis
Michal Rosen Zvi
Head of AI for Drug Discovery and Translational Medicine,
Merck
Mirella El Khoury
Senior Field Application Scientist,
Quanterix
Miro Venturi
Chief Executive Officer,
DIAMANTE Healthcare Consulting
Nikolas Stathonikos
Principal Investigator AI Development & Implementation,
UMC Utrecht
Nina Linder
Associate Professor,
Uppsala University
Nina Skorytchenko
Chief Executive Officer,
Avenna
Oskar Smrzka
CEO/CSO/Co-founder,
Ablevia
Paolo Paganetti
Head of Clinical & Laboratory,
Tivenix SA
Paul Mesange
Senior. Director, Lab Operations - Global Anatomic Pathology,
Labcorp
Paul Workman
Harrap Professor of Pharmacology and Therapeutics,
The Institute of Cancer Research, London
Peter Schüffler
Professor for Computational Pathology,
Technical University of Munich
Petra Kukkaro
Global Biomarker Diagnostic Director,
Novartis
Philip Beer
Chief Scientific Officer,
Step Pharma
Philip Zimmermann
Chief Executive Officer,
Prevision Medicine AG
Pierre Moulin
Chief Scientific Officer,
Deciphex Inc DBA Diagnexia US
Pim French
Professor Molecular Biology of Gliomas,
Erasmus MC
Przemek Fleszar
Advanced Workflow Specialist – Spatial Biology,
Leica Microsystems, Inc.
Rachel Agoglia
Manager, Global Pharma Applications & Bioinformatics,
Mission Bio
Raif Yuecel
Technical Director,
University of Exeter
Safia Agueni
Co-Founder,
Healthseed
Sam Cooper
Director Data/ML,
Engitix
Sanda Ljubicic
Director, Scientific Engagement, Cardiometabolic,
Labcorp
Sandra Jernström
CBDO / co-founder,
Vitroscope
Serena Bologna
Principal scientist,
FoRx Therapeutics
Simon Höllerer
Data Scientist,
Novartis
Stefanie Engler
Lab Manager,
University of Zurich
Sujana Sivapatham
Application Scientist,
Arcoris Bio
Susan Greenfield
Chief Executive Officer and Founder,
Neuro-Bio Ltd
Tatjana Crnogorac-Jurcevic
Professor of Molecular Pathology and Biomarkers,
Barts Cancer Institute, Queen Mary University of London
Taylor Jensen
Vice President, Head of Science Enterprise Oncology,
Labcorp
Thom Reuvers
Chief Operating Officer,
Methylomics BV
Tim Heinemann
Group Leader AI for Life Sciences ,
CSEM
Toni Verbeiren
Chief Executive Officer,
Data Intuitive
Torbjørn Furuseth
Chief Executive Officer & Co-Founder,
DoMore Diagnostics
Tuc Ahmed
Senior Director, Companion Diagnostics,
Labcorp
Ujjwal Mukund Mahajan
Associate Professor,
NIPER-S.A.S. nagar
Vasudev Kantae
Associate Director,
AstraZeneca
Vihanga Pahalawatta
Director,
AbbVie
Yixin Wang
Associate Director,
AstraZeneca

Getting There

Congress Center Basel
Messeplatz 21, CH-4058 Basel

By Rail

Basel is an international rail hub with direct ICE, IC and EC connections to Germany, Austria, Italy, France and the Benelux countries. Messe Basel can be reached in five to ten minutes from the three railway stations in Basel: SBB (Switzerland), SNCF (France) (Frankreich) and DB (Badischer Bahnhof, Germany)

By Tram

From the SBB/SNCF railway station, it’s a ten-minute journey on the No. 1 or 2 Tram to the “Messeplatz/Exhibition Square” stop where Messe Basel and the Congress Center are located. From Badischer Bahnhof railway station, “Messeplatz/Exhibition Square” is the second stop on the No. 2 or 6 tram.

By Air

EuroAirport Basel-Mulhouse-Freiburg is 15 minutes by car from Messe Basel. Basel municipal transport’s No. 50 bus additionally provides a straightforward connection from the airport to the SBB/SNCF railway station. From there, tram No. 1 or 2 will take you directly to Messeplatz/Exhibition Square. From Zurich Airport a direct rail connection will bring you to the SBB/SNCF railway station in Basel in less than an hour. For further information including a map and full directions, please visit: https://www.messe-basel.com/en/about-us/getting-to-messe-basel/

By Car

Basel is located at the point where the Swiss, German and French motorway networks all meet. The exhibition and congress site has its own direct link to the A2 motorway. The “Messe” exit will take you straight to the Messe Basel car park with its 1,200 parking spaces.

Information regarding accommodation for this event will be added soon

We are closely monitoring the official guidance from health authorities, local governments, and the World Health Organization in order to support the health and well-being of our global community. The health and safety of our staff, customers and clients remains our number one priority.

As we continue to move forward with hosting our events in-person in 2026, we’ve added a series of Health & Safety guidelines and precautions in order to prepare for event safety. We carry out risk assessments for all our events to evaluate fundamental considerations and how to cover multiple risk scenarios.

Oxford Global has learned that third-party companies (recently EHotel Services, Business Travel Management/btravelmanagement and Exhibitors Hotel Reservations Services) are targeting conference attendees with a fraudulent hotel booking scheme.

Please note that none of these third-party companies are associated with Oxford Global in any way, nor have Oxford Global authorised them to use their names or trademarks on information they send out to attendees.

If you are contacted by a third-party company by phone or email using Oxford Global’s name or the name of Biomarkers, CDx & Precision Medicine 2026 and offering accommodation services, we urge exhibitors and attendees to proceed with extreme caution before signing anything sent by these companies or entering into any conversation or replying to any emails sent from these third-party companies.

Precision Medicine Icon Light Blue

Basel.
13–14 October.

Twenty-one years of Biomarkers, CDx & Precision Medicine Europe. Co-located with NextGen Omics, Tech & Data. Four programmes, two days, one decision chain. Join us.